Igenica raises $5M; AgeneBio bags grant for PhIII-ready Alzheimer's program;

@FierceBiotech: Pfizer's hunting for safe M&A bets, not high-risk pipeline deals. Article | Follow @FierceBiotech

@JohnCFierce: $GSK and $NVS get EU clearance for the Big Swap -- selling some assets along the way. More | Follow @JohnCFierce

@DamianFierce: News to me: $AMGN's PCSK9 blocker will sell as Repatha, which sounds a bit like a mid-sized sports utility vehicle. | Follow @DamianFierce

> Igenica has raised $5 million of a $6.2 million offering, according to a recent SEC filing. The biotech raised $14 million from its venture backers--including Third Rock--about a year ago to move its lead cancer antibody into the clinic. Filing

> AgeneBio picked up a $900,000 grant from the Alzheimer's Drug Discovery Foundation to back its work on AGB101, which it describes as a Phase III-ready low dose formulation of an epilepsy drug. Release

> The OTC biotech Vaccinogen says it's closed a previously reported deal for $10 million to study its therapeutic cancer vaccine OncoVax. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: AdvaMed: China's push for hospitals to buy domestic devices all talk, no action. Article | Follow @FierceMedDev

@EmilyWFierce: Find out which med tech companies scored key device approvals in 2014 in @FierceMedDev's latest special report. Feature | Follow @EmilyWFierce

> St. Jude gains FlexAbility approval, lays out 2015 sales growth strategy. Article

> Illumina soars 32% in Q4 with sales of next-gen sequencing system. News

Pharma News

@FiercePharma: #Pfizer extricates itself from investor lawsuit with $400M payment. More | Follow @FiercePharma

@EricPFierce: Pfizer settles investor suit over marketing probe of Bexta for $400M. Story | Follow @EricPFierce

> Novartis braces for psoriasis pricing war as it preps for Cosentyx launch. Item

> Mylan said to be eyeing a $7B-plus bid for rising star Hikma. More

Drug Delivery News

> PARI snags FDA approval for cystic fibrosis nebulizer platform. News

> Microneedle patch maker Zosano Pharma raises $50M in IPO. Article

> Nanomed lifetime is an important aspect of delivery potential, scientists say. More

> Shire's intrathecally delivered candidate for Hunter syndrome gets FDA's Fast Track Designation. Report

> Australian team developing novel formulation to deliver common diabetes drug. Article

Diagnostics News

> Myriad settles patent feud with Invitae, Pathway Genomics over BRCA technology. News

> Roche nabs FDA OK for drug-resistant bacteria test. More

> Sequenom strikes a deal with Cypher Genomics to develop advanced noninvasive prenatal test. Report

> Sera Prognostics taps industry niche with preterm birth risk test. Story

> Roche's Ventana inches closer to FDA approval for lung cancer companion Dx. Article

Pharma Marketing News

> Novartis revs up Cosentyx launch as it braces for a psoriasis pricing war. News

> Express Scripts takes a bow for cutting $4B off hep C drug spending. Article

> Auryxia differentiation strategy, check. Next, Keryx has to persuade prescribers. Story

> Bayer, J&J launch new stroke study to pump up payer-persuading Xarelto data. More

> Valeant bets big on the Super Bowl with $4.5M toe-fungus ad. Article